FDA Acting Rx-to-OTC Switch Review Leader Prioritizes Personnel
This article was originally published in The Tan Sheet
Executive Summary
Shaw Chen, acting director of FDA’s Division of Nonprescription Clinical Evaluation, wants to stabilize the division’s staffing during a period of management transition. On the same CHPA conference panel, OTC monograph division chief Scott Furness shares some good news on time and extent applications.